Two recent studies suggest that periprocedural statin administration can prevent contrast-induced acute kidney injury in cardiac patients undergoing percutaneous coronary intervention and in renal patients undergoing angiography, with or without intervention. These studies support the routine administration of potent statins before contrast media infusion in these vulnerable patients.
Subscribe to Journal
Get full journal access for 1 year
only $17.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
McCullough, P. A. et al. Epidemiology and prognostic implications of contrast-induced nephropathy. Am. J. Cardiol. 98, 5K–13K (2006).
Chang, C. F. & Lin, C. C. Current concepts of contrast-induced nephropathy: a brief review. J. Chin. Med. Assoc. http://dx.doi.org/10.1016/j.jcma.2013.08.011.
Han, Y. et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J. Am. Coll. Cardiol. http://dx.doi.org/10.1016/j.jacc.2013.09.017.
Leoncini, M. et al. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome. Results from protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome (PRATO-ACS study). J. Am. Coll. Cardiol. http://dx.doi.org/10.1016/j.jacc.2013.04.105.
Ho, J. E. et al. Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the treating to new targets [TNT] study). Am. J. Cardiol. 109, 1761–1766 (2012).
Athyros, V. G., Karagiannis, A., Katsiki, N. & Mikhailidis, D. P. Relation of improvement in glomerular filtration rate with atorvastatin to reductions in heart failure morbidity. Am. J. Cardiol. 110, 763 (2012).
Quintavalle, C. et al. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation 126, 3008–3016 (2012).
Patti G. et al. Short-term, high-dose atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial). Am. J. Cardiol. 108, 1–7 (2011).
McCullough, P. A. Contrast-induced acute kidney injury. J. Am. Coll. Cardiol. 51, 1419–1428 (2008).
Pasceri, V. et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (atorvastatin for reduction of myocardial damage during angioplasty) study. Circulation 110, 674–678 (2004).
D. P. Mikhailidis has given talks, attended conferences and participated in trials and advisory boards sponsored by MSD and Genzyme. V. G. Athyros declares no competing interests.
About this article
Cite this article
Mikhailidis, D., Athyros, V. Short-term statin therapy for prevention of contrast-induced AKI. Nat Rev Nephrol 10, 8–9 (2014). https://doi.org/10.1038/nrneph.2013.249
Management of patients with type 2 diabetes mellitus and acute coronary syndrome: Better be safe than sorry!
Journal of Diabetes and its Complications (2019)
Non-Invasive Imaging for Evaluating Cardiovascular Involvement in Patients with Primary and Lupus Nephritis
The Open Rheumatology Journal (2019)
Contrast-induced acute kidney injury in diabetes mellitus: Clinical relevance and predisposing factors. Could statins be of benefit?
Journal of Diabetes and its Complications (2018)
Expert Review of Cardiovascular Therapy (2018)
The Open Cardiovascular Medicine Journal (2018)